TET2 antibody

Principal name

TET2 antibody

Alternative names for TET2 antibody

KIAA1546, Methylcytosine dioxygenase TET2

SwissProt ID

Q4JK59 (Mouse), Q6N021 (Human)

Gene ID

54790 (TET2)

Available reactivities

Can (Canine), Hu (Human), Ms (Mouse)

Available hosts

Goat, Rabbit, Mouse

Available applications

Enzyme Immunoassay (E), Paraffin Sections (P), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), Western blot / Immunoblot (WB), ChIP assay (ChIP)

Background of TET2 antibody

TET2 is frequently mutated in myelodysplastic syndromes, a heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites.
It Catalyzes the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation.
TET2 is Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.

General readings

Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIPL1-PDGFRA correlates. Leukemia 2009; 23:900-4.

  1. Quick-Filters:
  2. Cited (1)

5 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

TET2 antibody

TA311188 (4 ug/ml) staining of paraffin embedded Human Spleen. Steamed antigen retrieval with citrate buffer pH 6, HRP-staining. Goat Aff - Purified Can, Hu, Ms E, P
0.1 mg / €325.00
  OriGene Technologies, Inc.

TET2 (N-term) antibody

Western blot analysis of TET2 in SK-N-SH cell lysate with TET2 antibody at 1 ug/mL. Rabbit IgG Aff - Purified Hu E, WB
0.1 mg / €325.00
  OriGene Technologies, Inc.

TET2 antibody

WB using the antibody against TET2, diluted 1:2,000 (lane 1 and 2) or 1:1,000 (lane 3 and 4) in PBS containing 10% milk. The position of the protein of interest (expected MW 224 kDa) is indicated on the right; the marker (in kDa) is shown on the left. Figure 2B. WB on mouse E14 ES cells. The antibody was used at a dilution of 1:1,000. Mouse IgG1 Monoclol Purified Hu, Ms
50 µg / €325.00
  OriGene Technologies, Inc.

TET2 antibody

Western blot analysis of TET2 in 3T3 cell lysate with TET2 antibody at 1 ug/mL. Rabbit IgG Purified Hu, Ms WB
0.1 mg / €325.00
  OriGene Technologies, Inc.

TET2 (N-term) Control Peptide

TET2
50 µg / €160.00
  Acris Antibodies GmbH

5 Item(s)

per page
  • LinkedIn